Durysta (AbbVie)
A biodegradable 10 mcg bimatoprost implant injected into the anterior chamber. The label says it should not be readministered to an eye that already received one.
Durysta PIGlaucoma Care · Drug Delivery
Sustained-Release Glaucoma Implants Durysta and iDose TR.
Two intracameral implants deliver a prostaglandin analog inside the eye, giving patients who struggle with drops another way to lower pressure. They are placed by an ophthalmic surgeon; the referring practice identifies candidates and monitors them afterward.
10 mcgbimatoprost in a Durysta implant
75 mcgtravoprost in an iDose TR implant
J7351HCPCS code for the bimatoprost implant, per microgram
J7355HCPCS code for the travoprost implant, per microgram
How they work
Drug delivered inside the anterior chamber
Both implants release a prostaglandin analog in the anterior chamber, close to the outflow pathways, instead of relying on daily drops.
iDose TR (Glaukos)
A 75 mcg travoprost implant anchored in the sclera at the angle through a small temporal corneal incision.
iDose TR PIShared indication
Both are indicated to reduce intraocular pressure in open-angle glaucoma or ocular hypertension.
LabelsEndothelial checks
Both labels address corneal endothelial cell loss; iDose TR requires specular microscopy before each dose.
LabelsChoosing between them
The implants differ in material, placement and how often they can be given.
- Biodegradable versus anchored implant
- Single administration versus readministration
- Endothelial screening requirements
-
Readministration
Durysta is limited to one implant per eye. iDose TR may be readministered, but not more than once a year, with the old implant removed after the new one is placed.
-
Efficacy
Durysta lowered pressure by about 5 to 8 mmHg from a mean baseline of 24.5 mmHg in two 20-month trials compared with timolol.
-
iDose TR trials
In two 12-month trials against timolol, pressure fell about 6.6 to 8.4 mmHg from a mean baseline of 24 mmHg during the first three months.
-
Storage
Durysta is refrigerated at 2°C to 8°C. iDose TR is stored at 2°C to 25°C and must not be frozen.
Co-management
Referring an implant candidate
Good candidates have open angles, a healthy endothelium and a reason to reduce drop dependence.
Screen
Confirm open angles on gonioscopy, no active infection or inflammation, and no contraindicated corneal history.
Refer
Send the pressure history, current medications, OCT, fields and any endothelial cell counts to the surgeon.
Monitor
Follow pressure, inflammation and corneal status after placement, and plan the next step when the effect wanes.
Label details
Product comparison
| Drug and dose | Durysta: bimatoprost 10 mcg. iDose TR: travoprost 75 mcg |
|---|---|
| Placement | Durysta: intracameral injection. iDose TR: anchored at the iridocorneal angle |
| Repeat dosing | Durysta: not readministered. iDose TR: not more than once per year |
| HCPCS | Durysta: J7351 per 1 mcg. iDose TR: J7355 per 1 mcg, billed as 75 units |
| Procedure code for iDose TR | 0660T, with 0661T for removal and reimplantation |
Durysta contraindications
- Active or suspected ocular or periocular infection
- Corneal endothelial cell dystrophy such as Fuchs' dystrophy
- Prior corneal or endothelial cell transplant
- Absent or ruptured posterior lens capsule
- Hypersensitivity to bimatoprost or other components
iDose TR contraindications
- Ocular or periocular infection
- Corneal endothelial dystrophy
- Prior corneal or endothelial cell transplant
- Hypersensitivity to travoprost or other components
Shared warnings
- Corneal adverse reactions and endothelial cell loss
- Caution with narrow angles or angle obstruction
- Macular edema
- Intraocular inflammation
- Increased iris pigmentation that may be permanent
- Endophthalmitis after intraocular procedures
Questions about glaucoma implants
Who places the implant?
An ophthalmic surgeon, under magnification and aseptic conditions. The referring optometrist identifies candidates and manages follow-up.
Can Durysta be repeated?
No. Its label states it should not be readministered to an eye that received a prior Durysta implant.
How often can iDose TR be given?
Readministration is not recommended more than once per year, and baseline endothelial cell density must be established before each dose.
What are the most common side effects?
For Durysta, conjunctival hyperemia in 27%. For iDose TR, increased pressure, iritis, dry eye and visual field defects in 2% to 6%.
Do patients still need drops?
Some do. The implants lower pressure, but stage, target and response decide whether additional therapy is needed.
How are they billed?
The drug is billed with its J-code in microgram units, plus the procedure code. iDose TR uses J7355 at 75 units with 0660T. Confirm payer rules first.
References
- Durysta (bimatoprost implant) Prescribing Information, AbbVie. Label
- iDose TR (travoprost intracameral implant) Prescribing Information, Glaukos. Label
- Glaukos. 2026 iDose billing and coding quick reference guide. Glaukos
- CMS HCPCS J7351, injection, bimatoprost, intracameral implant, 1 microgram (effective October 1, 2020). HCPCS lookup
Give drop-weary patients another option
Identify candidates in your glaucoma panel and refer them to a surgeon who places implants.
Written for licensed eye care professionals. Durysta is a trademark of AbbVie; iDose is a trademark of Glaukos. Review the full Prescribing Information for each product before referral or use. Coding information is general; confirm with each payer.